Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Invex Therapeutics's pretax income for the
six
months ended in Dec. 2025 was A$-0.72 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.84 Mil.
Invex Therapeutics's pretax margin was %.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics Pre-Tax Income Related Terms
Invex Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IXC vs VRTX, REGN, RVMD: Pre-Tax Income Comparison
For the Biotechnology subindustry, Invex Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics (ASX:IXC) has a Pre-Tax Income of A$-0.84 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Pre-Tax Income too high?
Invex Therapeutics' current Pre-Tax Income is A$-0.84 Mil. Overall, Invex Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Pre-Tax Income compare to VRTX and REGN?
Invex Therapeutics' Pre-Tax Income of A$-0.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Pre-Tax Income is A$-0.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Pre-Tax Income of A$-0.84 Mil. The current Pre-Tax Income is A$-0.84 Mil. Invex Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Pre-Tax Income is A$-0.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
28GF Score
Get the complete analysis for ASX:IXC
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 
